Stockscreener 앱 받기
0.7813
5.01%
0.0373
시간 외 거래:
.80
0.0187
+2.39%
Coherus Biosciences Inc 주식(CHRS)의 최신 뉴스
Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Growth in Short Interest - MarketBeat
Los Angeles Capital Management LLC Has $967,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - MarketBeat
Coherus stock rallies 19% on Q3 earnings, Udenyca production update - MSN
Robert W. Baird Has Lowered Expectations for Coherus BioSciences (NASDAQ:CHRS) Stock Price - MarketBeat
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2024 Earnings Call Transcript - Insider Monkey
Coherus BioSciences' (CHRS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Supply Challenges - GuruFocus.com
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Coherus BioSciences Reports Strong Q3 2024 Growth - TipRanks
Coherus BioSciences earnings beat by $0.15, revenue topped estimates - Investing.com Canada
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Coherus BioSciences: Q3 Earnings Snapshot - San Antonio Express-News
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30% - Simply Wall St
Coherus BioSciences Q3 2024 Earnings Preview - MSN
CHRS stock touches 52-week low at $0.71 amid market challenges - Investing.com Australia
Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to K - GuruFocus.com
Coherus BioSciences (CHRS) to Release Quarterly Earnings on Wednesday - MarketBeat
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewswire
Brokerages Set Coherus BioSciences, Inc. (NASDAQ:CHRS) Price Target at $7.13 - MarketBeat
CHRS stock plunges to 52-week low, hitting $0.79 By Investing.com - Investing.com Canada
CHRS stock plunges to 52-week low, hitting $0.79 - Investing.com India
Warning: CHRS is at high risk of performing badly - MSN
Such Is The Power Of Coherus Biosciences Inc (NASDAQ: CHRS) - Stocks Register
Exclusive-Russia to use ship-to-ship LNG loadings to free up ice-class tankers By Reuters - Investing.com
Coherus BioSciences (NASDAQ:CHRS) Lowered to "Hold" at StockNews.com - MarketBeat
CHRS stock touches 52-week low at $0.85 amid market challenges - Investing.com India
CHRS stock touches 52-week low at $0.85 amid market challenges By Investing.com - Investing.com South Africa
Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Increase in Short Interest - MarketBeat
How should investors view Coherus Biosciences Inc (CHRS)? - US Post News
Coherus Biosciences Inc Inc. (CHRS) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
StockNews.com Upgrades Coherus BioSciences (NASDAQ:CHRS) to “Buy” - Defense World
Financial Metrics Unveiled: Coherus Biosciences Inc (CHRS)’s Key Ratios in the Spotlight - The Dwinnex
AQR Capital Management LLC Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
719,999 Shares in Coherus BioSciences, Inc. (NASDAQ:CHRS) Acquired by AQR Capital Management LLC - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Upgraded at StockNews.com - MarketBeat
CHRS stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Coherus Biosciences Inc (CHRS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Coherus cancer drug undercuts Merck's Keytruda - MSN
3.66%
1.11%
자본화:
|
볼륨(24시간):